https://billeveast.com/us-fda-revised-mapp-on-cgmp-surveillance-inspections/ 2023-07-14T10:11:44+00:00 https://billeveast.com/european-commision-ec-proposal-for-regulation-of-ema-fees/ 2023-07-07T08:38:39+00:00 https://billeveast.com/eu-regulation-with-specific-rules-for-northern-ireland-published/ 2023-06-28T09:00:12+00:00 https://billeveast.com/apic-published-document-data-integrity-frequently-asked-questions-faq/ 2023-06-28T08:57:58+00:00 https://billeveast.com/ema-update-on-gacp-revision/ 2023-06-28T08:53:54+00:00 https://billeveast.com/the-australian-tga-is-seeking-feedback-on-the-risk-classification-of-medical-devices/ 2023-06-23T07:49:20+00:00 https://billeveast.com/analytical-procedures-for-mrna-vaccine-quality-usp-draft-guidelines-2nd-edition/ 2023-06-16T13:08:13+00:00 https://billeveast.com/ema-updates-qa-documents-on-centralised-procedures/ 2023-06-13T11:36:42+00:00 https://billeveast.com/ema-eu-us-mutual-recognition-agreement-for-veterinary-medicines-inspections/ 2023-06-06T15:09:18+00:00 https://billeveast.com/apic-published-ich-m7-how-to-do-document/ 2023-05-29T13:27:24+00:00 https://billeveast.com/what-ema-publishes-and-when-guide-to-information-on-human-medicines-evaluated-by-ema/ 2023-05-24T11:04:04+00:00 https://billeveast.com/ema-published-guidance-for-industry-to-prevent-medicine-shortages/ 2023-05-22T10:03:23+00:00 https://billeveast.com/medical-cannabis-act-in-germany/ 2023-05-22T10:02:17+00:00 https://billeveast.com/new-ema-guidelines-and-revisions-in-gmp-area/ 2023-05-17T12:06:10+00:00 https://billeveast.com/guidelines-for-the-implementation-of-article-54-of-the-medicinal-products-act-the-issue-of-marketing-authorisation-as-an-urgent-measure/ 2023-05-12T08:25:08+00:00 https://billeveast.com/consequences-from-the-new-eu-commission-proposal-on-gmp/ 2023-05-10T11:31:22+00:00 https://billeveast.com/electronic-product-information-epi-topra-webinar-with-katja-pecjak-and-britt-vermeij-as-speakers/ 2023-05-03T05:12:03+00:00 https://billeveast.com/pfas-ban-impact-on-pharmaceuticals/ 2023-04-26T06:06:13+00:00 https://billeveast.com/modernization-of-the-current-variations-system/ 2023-04-24T08:14:05+00:00 https://billeveast.com/who-published-draft-on-revised-gmp-for-excipients-in-pharmaceutical-products/ 2023-04-17T12:42:16+00:00 https://billeveast.com/what-is-iso-13485/ 2023-04-14T08:42:22+00:00 https://billeveast.com/ich-publication-of-the-introductory-presentation-on-ich-q9-r1/ 2023-04-06T09:06:35+00:00 https://billeveast.com/ema-update-on-nitrosamines-impurities/ 2023-04-06T05:24:02+00:00 https://billeveast.com/clinical-performance-study-protocol-following-the-iso-20916/ 2023-03-29T10:26:47+00:00 https://billeveast.com/the-most-important-dates-and-requirements-related-to-legacy-devices/ 2023-03-10T08:01:35+00:00 https://billeveast.com/dia-session-electronic-product-information-for-eu-medicines-the-road-ahead-for-the-implementation-of-the-eu-epi/ 2023-03-02T08:22:49+00:00 https://billeveast.com/iso-20916-clinical-performance-studies-for-ivd-and-iso-14155-clinical-evaluation-for-md/ 2023-02-07T10:47:33+00:00 https://billeveast.com/individual-deviation-from-the-terms-of-marketing-authorisation-oos/ 2023-02-01T09:55:51+00:00 https://billeveast.com/ich-published-revised-ich-q9r1-quality-risk-management/ 2023-01-31T13:29:37+00:00 https://billeveast.com/emas-2023-veterinary-info-day/ 2023-01-27T12:36:19+00:00 https://billeveast.com/fees-in-slovenia-and-croatia/ 2023-01-26T10:07:11+00:00 https://billeveast.com/european-green-deal-draft-regulation-on-packaging-and-packaging-waste-and-impact-on-medicines/ 2023-01-26T10:03:46+00:00 https://billeveast.com/3rs-working-party/ 2023-01-26T07:58:38+00:00 https://billeveast.com/emas-expectations-for-bootstrapping/ 2023-01-25T07:55:53+00:00 https://billeveast.com/update-on-the-ema-checklists-for-changes-variations-for-type-ii-non-clinical-variations/ 2023-01-25T07:20:04+00:00 https://billeveast.com/ema-perspective-on-using-mechanistic-models-to-support-development-of-complex-generic-drug-products/ 2023-01-19T11:07:09+00:00 https://billeveast.com/wp-content/uploads/2023/01/PBBE.png https://billeveast.com/10th-slovenian-meeting-on-clinical-pharmacology-safe-use-of-medicines/ 2023-01-16T15:44:01+00:00 https://billeveast.com/artificial-intelligence-in-regulatory-affairs/ 2023-01-16T08:39:01+00:00 https://billeveast.com/educational-materials/ 2023-01-12T12:12:02+00:00 https://billeveast.com/clinical-trials-raw-data-pilot-first-raw-data-submission-has-been-received/ 2023-01-10T12:56:40+00:00 https://billeveast.com/role-of-eu-authorised-representative/ 2023-01-10T10:16:56+00:00 https://billeveast.com/ich-draft-guideline-for-bioequivalence-testing/ 2023-01-10T10:15:53+00:00 https://billeveast.com/wp-content/uploads/2023/01/ICH-bioequivalence.png https://billeveast.com/the-european-commission-has-given-the-green-light-to-an-extension-of-the-transition-periods-for-the-mdr-and-ivdr/ 2023-01-06T16:12:09+00:00 https://billeveast.com/european-mdcg-group-published-guidance-on-a-performance-study/ 2023-01-06T14:57:39+00:00 https://billeveast.com/european-database-on-medical-devices/ 2023-01-06T12:11:30+00:00 https://billeveast.com/wp-content/uploads/2023/01/UDI.png https://billeveast.com/wp-content/uploads/2023/01/EUDAMED.png https://billeveast.com/the-future-strategy-for-batch-testing-of-medicinal-products-in-great-britain/ 2022-12-22T15:34:46+00:00 https://billeveast.com/european-commission-position-paper-on-hybrid-audits/ 2022-12-22T15:30:56+00:00 https://billeveast.com/danish-authority-updated-document-on-requirements-for-a-qualified-person/ 2022-12-16T08:32:55+00:00 https://billeveast.com/an-extension-of-the-transitional-period-for-mdr-and-ivdr/ 2022-12-13T12:26:16+00:00 https://billeveast.com/proposal-for-restriction-on-the-placing-on-the-market-of-microplastics/ 2022-12-12T14:40:30+00:00 https://billeveast.com/adoption-of-ich-q13-guideline-on-continuous-manufacturing/ 2022-12-06T14:29:51+00:00 https://billeveast.com/ema-risk-management-information-day/ 2022-12-05T16:17:00+00:00 https://billeveast.com/annex-1-final-version-and-its-impacts-current-requirements-on-aseptic-manufacturing/ 2022-12-05T16:01:48+00:00 https://billeveast.com/european-commission-changed-labelling-requirements-for-investigational-medicinal-products/ 2022-12-05T08:46:37+00:00 https://billeveast.com/public-consultation-on-concept-paper-on-the-revision-of-annex-11-of-the-eu-gmp-computerised-systems/ 2022-12-01T09:56:45+00:00 https://billeveast.com/ipec-has-updated-excipient-stability-guide-for-pharmaceutical-excipients/ 2022-11-23T08:27:08+00:00 https://billeveast.com/us-fda-warning-letters-of-the-fiscal-year-2022/ 2022-11-21T08:20:43+00:00 https://billeveast.com/consequences-of-ban-on-titanium-dioxide-e171-for-medicines/ 2022-11-17T14:17:54+00:00 https://billeveast.com/different-labelling-of-medicinal-products/ 2022-11-15T09:43:41+00:00 https://billeveast.com/vulnerabilities-in-global-supply-chains-reasons-and-possible-solutions/ 2022-11-15T08:26:49+00:00 https://billeveast.com/uk-mhra-announces-resumption-of-international-gmp-inspections/ 2022-11-15T08:06:45+00:00 https://billeveast.com/pharmacovigilance-world-2022/ 2022-11-10T10:37:02+00:00 https://billeveast.com/mhra-announced-the-delay-in-implementation-of-british-medical-device-regulation/ 2022-11-10T10:17:23+00:00 https://billeveast.com/information-about-marketed-medicinal-products/ 2022-11-02T11:49:09+00:00 https://billeveast.com/transition-to-the-mdr-and-ivdr/ 2022-10-28T12:07:20+00:00 https://billeveast.com/person-responsible-for-pharmacovigilance/ 2022-10-28T11:01:44+00:00 https://billeveast.com/two-compliance-program-guides-cpgs-on-gmp-inspections-updated-by-us-fda/ 2022-10-27T10:59:57+00:00 https://billeveast.com/draft-guidance-on-boundary-and-combination-products-published-by-tga/ 2022-10-27T10:56:28+00:00 https://billeveast.com/the-importance-of-mitochondrial-toxicity-assessment-in-drug-development/ 2022-10-27T09:28:34+00:00 https://billeveast.com/ema-published-revised-qa-for-marketing-authorisation-holders-on-nitrosamine-impurities-in-human-medicinal-products/ 2022-10-27T09:26:24+00:00 https://billeveast.com/the-chmp-recommended-granting-marketing-authorisation-for-dengue-tetravalent-vaccine/ 2022-10-25T09:11:19+00:00 https://billeveast.com/requirements-for-documentation-in-annex-ii/ 2022-10-25T08:52:52+00:00 https://billeveast.com/european-pharmacovigilance-congress-2022/ 2022-10-25T08:01:16+00:00 https://billeveast.com/ema-published-draft-quality-guidelines-for-synthetic-peptides-and-oligonucleotides/ 2022-09-29T14:52:21+00:00 https://billeveast.com/fda-issued-draft-data-integrity-guidance-computer-software-assurance-for-production-and-quality-system-software-for-consultation/ 2022-09-26T14:17:29+00:00 https://billeveast.com/good-documentation-practices-in-gmp-and-gdp-regulated-environments/ 2022-09-22T08:06:43+00:00 https://billeveast.com/usp-and-fda-propose-updates-to-good-storage-and-distribution-practices/ 2022-09-19T06:52:00+00:00 https://billeveast.com/i-spoc-registration-deadline-by-2nd-september/ 2022-09-02T13:57:16+00:00 https://billeveast.com/ema-has-published-3-year-work-plan-for-the-quality-domain/ 2022-08-31T11:10:46+00:00 https://billeveast.com/topra-in-cee-labelling-of-marketed-drugs-in-cee-region/ 2022-08-30T17:47:05+00:00 https://billeveast.com/the-cep-of-the-future-edqm-workshop-with-stakeholders/ 2022-08-30T17:44:06+00:00 https://billeveast.com/11th-symposium-on-herbal-medicinal-products-in-europe-2022-with-satellite-symposium-on-medicinal-cannabis/ 2022-09-05T06:18:09+00:00 https://billeveast.com/topra-annual-symposium-2022/ 2022-09-17T06:20:41+00:00 https://billeveast.com/amendment-of-the-rules-on-technical-and-organisational-measures-for-the-storage-of-hazardous-chemicals/ 2022-08-30T07:24:32+00:00 https://billeveast.com/update-on-emas-question-and-answer-document-for-mahs-regarding-nitrosamine-impurities/ 2022-08-25T13:22:58+00:00 https://billeveast.com/data-integrity-in-gmp-environment/ 2022-08-24T06:38:32+00:00 https://billeveast.com/revised-gamp5-guidelines-published/ 2022-08-11T07:36:27+00:00 https://billeveast.com/strokovni-sodelavecka-za-kakovost-qp-rp-quality-expert-qp-rp-m-z/ 2022-08-10T15:14:50+00:00 https://billeveast.com/european-commission-published-common-specifications-for-certain-high-risk-ivds/ 2022-08-09T11:10:51+00:00 https://billeveast.com/us-fda-revises-guidance-for-industry-non-penicillin-beta-lactam-drugs-a-cgmp-framework-for-preventing-cross-contamination-2/ 2022-08-09T11:02:48+00:00 https://billeveast.com/ema-to-address-nitrosamine-impurities-in-upcoming-revision-of-active-substances-guidance/ 2022-08-05T07:11:06+00:00 https://billeveast.com/microbial-monitoring-of-compressed-gases-used-in-pharmaceutical-manufacturing/ 2022-08-01T10:10:40+00:00 https://billeveast.com/status-of-implementation-of-the-whistleblower-directive/ 2022-07-29T11:10:45+00:00 https://billeveast.com/us-fda-published-new-guidances-for-industry/ 2022-07-27T14:36:07+00:00 https://billeveast.com/fda-approved/ 2022-07-22T08:47:35+00:00 https://billeveast.com/planned-revision-of-usp-description-and-relative-solubility-reference-table/ 2022-07-21T06:38:34+00:00 https://billeveast.com/ema-has-published-the-questions-and-answers-on-titanium-dioxide/ 2022-07-15T09:38:55+00:00 https://billeveast.com/management-of-changes-to-authorized-biocidal-products/ 2022-07-14T06:11:30+00:00 https://billeveast.com/introductory-training-on-ich-q3dr2-guideline-for-elemental-impurities/ 2022-07-13T07:12:20+00:00 https://billeveast.com/ema-updated-iris-guide-for-applicants/ 2022-07-01T09:45:03+00:00 https://billeveast.com/us-fda-revises-guidance-for-industry-non-penicillin-beta-lactam-drugs-a-cgmp-framework-for-preventing-cross-contamination/ 2022-06-29T14:38:49+00:00 https://billeveast.com/usa-fda-proposes-new-rules-for-wholesale-drug-distributors-and-third-party-logistics-providers/ 2022-06-28T07:49:30+00:00 https://billeveast.com/gap-analysis-of-quality-management-system-in-gmp-environment/ 2022-06-23T13:21:39+00:00 https://billeveast.com/upcoming-changes-to-reach-information-requirements/ 2022-06-22T06:52:54+00:00 https://billeveast.com/supplier-audit-management/ 2022-06-21T08:32:15+00:00 https://billeveast.com/ema-publishes-annual-report-2021-on-10th-june-2022/ 2022-06-20T13:39:42+00:00 https://billeveast.com/labelling-requirements-for-investigational-medicinal-products/ 2022-06-16T07:33:12+00:00 https://billeveast.com/importation-of-medicinal-products-in-eu-and-new-annex-21/ 2022-06-15T07:39:43+00:00 https://billeveast.com/cannabidiol-novel-food-evaluations-on-hold-due-to-data-gaps-and-uncertainties-about-potential-hazards-related-to-cbd-intake/ 2022-06-14T10:08:37+00:00 https://billeveast.com/ema-adopts-first-list-of-critical-medicines-for-covid-19/ 2022-06-09T16:26:24+00:00 https://billeveast.com/update-of-qa-list-for-the-submission-of-variations-for-human-medicinal-products/ 2022-06-08T07:07:41+00:00 https://billeveast.com/standalone-regulations-for-in-vitro-diagnostic-medical-devices-in-switzerland/ 2022-06-06T11:52:00+00:00 https://billeveast.com/new-template-for-the-nitrosamine-risk-evaluation/ 2022-06-03T08:58:49+00:00 https://billeveast.com/distribution-of-medicinal-products-requiring-special-storage-conditions/ 2022-06-02T07:18:41+00:00 https://billeveast.com/ema-publishes-final-guidelines-on-quality-and-specifications-for-herbal-medicinal-products/ 2022-06-01T08:20:25+00:00 https://billeveast.com/theranostics-patient-centered-care-at-its-best/ 2022-05-30T08:30:28+00:00 https://billeveast.com/supplier-management-in-pharmaceutical-environment/ 2022-05-30T06:46:44+00:00 https://billeveast.com/wp-content/uploads/2022/05/Supplier-approval-process.jpg https://billeveast.com/reminder-for-in-vitro-diagnostic-medical-device-sector-ivdr-is-now-fully-applicable/ 2022-05-27T12:09:58+00:00 https://billeveast.com/ema-has-updated-good-clinical-practice-annexes/ 2022-05-26T06:19:08+00:00 https://billeveast.com/revised-ich-q3d-r2-guideline-on-elemental-impurities/ 2022-05-25T06:27:22+00:00 https://billeveast.com/japans-pmda-published-english-version-of-the-revised-global-principles-for-clinical-trials/ 2022-05-19T06:18:16+00:00 https://billeveast.com/ema-updates-questions-answers-on-parallel-distribution/ 2022-05-18T05:47:21+00:00 https://billeveast.com/18th-adaptation-to-technical-and-scientific-progress-to-regulation-ec-no-1272-2008-clp-regulation-was-published-on-3rd-may-2022/ 2022-05-17T09:28:42+00:00 https://billeveast.com/public-consultation-concerning-the-physical-attendance-and-the-location-of-personal-residency-of-the-qp/ 2022-05-17T07:01:21+00:00 https://billeveast.com/emas-update-on-mutual-recognition-agreements/ 2022-05-12T07:29:33+00:00 https://billeveast.com/future-of-pharmacovigilance/ 2022-05-11T09:44:31+00:00 https://billeveast.com/cmdh-best-practice-guide-for-authorisation-of-non-prescription-medicines-in-the-dcp-and-mrp/ 2022-05-10T09:40:15+00:00 https://billeveast.com/validation-of-excel-spreadsheets/ 2022-05-09T08:34:46+00:00 https://billeveast.com/ema-has-released-comments-on-the-current-ich-guideline-q9-r1-quality-risk-management/ 2022-05-05T07:14:36+00:00 https://billeveast.com/brexit-2/ 2022-05-04T08:56:20+00:00 https://billeveast.com/revised-us-fda-quality-metrics-program/ 2022-05-03T08:44:24+00:00 https://billeveast.com/targeted-revision-of-the-cosmetics-regulation/ 2022-05-02T06:53:37+00:00 https://billeveast.com/monitoring-of-microbial-contamination-of-sewage-drains-in-manufacturing-premises/ 2022-04-28T19:53:56+00:00 https://billeveast.com/total-organic-carbon-test-toc/ 2022-04-27T17:18:21+00:00 https://billeveast.com/fda-issues-final-guidance-regarding-bioavailability-studies-in-ndas-or-inds/ 2022-04-25T13:35:14+00:00 https://billeveast.com/two-cmdh-guidance-documents-recently-changed/ 2022-04-22T10:42:01+00:00 https://billeveast.com/ich-harmonized-guidelines-q14-and-q2r2/ 2022-04-20T13:34:44+00:00 https://billeveast.com/a-look-at-batch-record-review/ 2022-04-19T06:52:02+00:00 https://billeveast.com/who-publishes-practical-guide-on-how-to-temperature-map-cold-chain-equipment-and-storage-areas/ 2022-04-14T07:21:05+00:00 https://billeveast.com/tga-updated-the-quality-rules-for-medicinal-cannabis/ 2022-04-13T07:13:35+00:00 https://billeveast.com/implementation-and-preparedness-plan-of-the-ivdr-endorsed-by-mdcg/ 2022-04-12T07:26:19+00:00 https://billeveast.com/slovenian-siq-newly-designated-notified-body/ 2022-04-04T07:16:48+00:00 https://billeveast.com/france-enters-the-medical-cannabis-industry/ 2022-04-01T08:02:03+00:00 https://billeveast.com/combination-products-and-eu-mdr-2017-745-regulation/ 2022-03-30T08:33:48+00:00 https://billeveast.com/european-commission-approach-for-pharmaceuticals-in-the-environment/ 2022-03-30T07:11:12+00:00 https://billeveast.com/emas-extended-mandate/ 2022-03-29T10:46:38+00:00 https://billeveast.com/risk-assessment-of-gdp-supply-chain-routes/ 2022-03-28T10:18:20+00:00 https://billeveast.com/wp-content/uploads/2022/03/Screenshot-2022-03-28-140224.jpg https://billeveast.com/certificate-of-suitability-cep-applications/ 2022-03-25T11:08:07+00:00 https://billeveast.com/regular-interval-for-gdp-self-inspections/ 2022-03-24T14:28:40+00:00 https://billeveast.com/generic-drug-science-and-research-initiatives-public-workshop/ 2022-03-24T07:59:17+00:00 https://billeveast.com/data-analysis-and-real-world-interrogation-network-darwin-eu/ 2022-03-23T16:45:18+00:00 https://billeveast.com/eu-gmp-annex-1-manufacture-of-sterile-medicinal-products/ 2022-03-23T13:05:22+00:00 https://billeveast.com/eu-mdr-and-its-impact-on-swiss-eu-relations/ 2022-03-22T11:59:10+00:00 https://billeveast.com/clinical-trials-information-system-ctis-walk-in-clinic/ 2022-03-22T11:48:19+00:00 https://billeveast.com/gmp-gdp-and-gcp/ 2022-03-21T13:23:56+00:00 https://billeveast.com/pharma-adopting-to-green-initiatives/ 2022-03-21T13:07:38+00:00 https://billeveast.com/medicinal-products-containing-estragole/ 2022-03-17T15:18:42+00:00 https://billeveast.com/future-of-united-kingdom-clinical-trial-legislation-and-impact-on-imps/ 2022-03-17T10:25:26+00:00 https://billeveast.com/clinical-trials-during-the-covid-19-pandemic/ 2022-03-16T16:27:00+00:00 https://billeveast.com/electronic-instructions-for-md/ 2022-03-15T10:10:39+00:00 https://billeveast.com/veterinary-medicines/ 2022-03-14T09:09:46+00:00 https://billeveast.com/nitrosamine-risk-assessments/ 2022-03-11T09:07:27+00:00 https://billeveast.com/good-agricultural-and-collection-practice-gacp/ 2022-03-10T12:09:42+00:00 https://billeveast.com/gmp-guide/ 2022-03-07T08:06:13+00:00 https://billeveast.com/future-of-tio2/ 2022-03-05T16:59:02+00:00 https://billeveast.com/medical-devices/ 2022-03-04T11:44:32+00:00 https://billeveast.com/investigational-medicinal-products-imps/ 2022-03-03T10:15:09+00:00 https://billeveast.com/focus-on-ensuring-a-high-and-reproducible-quality-of-medicinal-cannabis/ 2022-03-01T14:16:29+00:00 https://billeveast.com/published-annex-21-to-the-eu-gmp-guidelines/ 2022-02-28T16:12:52+00:00 https://billeveast.com/the-clinical-trials-information-system-ctis-has-gone-live/ 2022-02-13T09:25:54+00:00 https://billeveast.com/our-new-director-of-regulatory-affairs/ 2021-08-18T11:59:15+00:00 https://billeveast.com/mdr/ 2021-05-26T07:21:27+00:00 https://billeveast.com/tio2-safety/ 2021-05-06T20:36:37+00:00 https://billeveast.com/medical-translations/ 2020-09-18T10:12:50+00:00 https://billeveast.com/environmental-risk-assessment-era/ 2020-06-12T06:41:08+00:00 https://billeveast.com/gcp-audits/ 2020-04-22T06:39:55+00:00 https://billeveast.com/bpe-offers-you-a-prrc-for-your-medical-devices/ 2020-03-09T11:14:36+00:00 https://billeveast.com/billev-pharma-east-was-managing-the-whole-decentralized-regulatory-procedure-to-gain-approval/ 2020-02-09T11:15:38+00:00 https://billeveast.com/wp-content/uploads/2020/02/Lidbree-1024x274.jpg https://billeveast.com/lets-meet-at-the-13th-pharmacovigilance-conference/ 2020-01-10T07:42:01+00:00 https://billeveast.com/approaching-deadline-for-reporting-the-outcome-of-nitrosamine-risk-evaluations/ 2020-01-09T07:43:00+00:00 https://billeveast.com/bpe-can-offer-you-a-contractual-prrc-for-your-medical-devices/ 2019-07-23T06:45:13+00:00 https://billeveast.com/billev-pharma-east-can-help-you-with-qp-release-and-gmp-audits-preparation/ 2019-03-29T07:46:04+00:00 https://billeveast.com/are-you-ready-for-brexit/ 2019-02-24T07:46:59+00:00 https://billeveast.com/billev-pharma-east-at-the-annual-pharmacovigilance-and-regulatory-affairs-conference-2019/ 2019-02-13T07:53:43+00:00 https://billeveast.com/updates-to-eafs-2/ 2018-02-06T08:38:51+00:00 https://billeveast.com/updates-to-eafs/ 2018-02-06T07:55:53+00:00 https://billeveast.com/billev-pharma-east-experience-from-conference-in-london-2/ 2018-02-05T08:39:29+00:00 https://billeveast.com/billev-pharma-east-experience-from-conference-in-london/ 2018-02-05T07:56:33+00:00 https://billeveast.com/fdas-may-2018-ectd-deadline/ 2018-01-30T08:41:35+00:00 https://billeveast.com/phv-and-ra-conference-in-london-from-24th-26th-of-january/ 2018-01-09T08:42:15+00:00 https://billeveast.com/spor-going-live-15-december-2017/ 2017-12-15T08:42:55+00:00 https://billeveast.com/lets-meet-at-the-11th-pharmacovigilance-conference/ 2017-11-23T08:43:39+00:00 https://billeveast.com/wp-content/uploads/2021/04/PHV18-Speaker-banner-VG.png https://billeveast.com/nees-is-out-from-mrp-ectd-only-for-all-submissions-in-eu-procedures-from-1-january-2018/ 2017-11-13T08:45:17+00:00 https://billeveast.com/pharmacovigilance-conference/ 2017-11-08T08:46:12+00:00 https://billeveast.com/cphi-worldwide-frankfurt/ 2017-09-16T07:47:37+00:00 https://billeveast.com/brexit/ 2017-09-16T07:46:54+00:00 https://billeveast.com/health-based-exposure-limits-hbels/ 2017-09-13T07:48:51+00:00